Christophe F. Grosset
Strategic Lead - Marketscreener Italy
Because finance isn’t just about numbers, Christophe F. Grosset explores the ideas, trends and people reshaping it.
Between Milan and Geneva, he highlights innovation, markets, and those reinventing the industry.
Follow him on MarketScreener Italia — where finance meets curiosity.
UCB raises guidance on strength of its two flagship treatments, analysts applaud
Supported by sustained commercial momentum, the Belgian biopharmaceutical group (+13.05%, at EUR240.20) announced another increase in its financial targets for FY 2026. Strong revenue growth is generating significant operating leverage, allowing for a marked expansion in margins.
22 October 2026 at 08:05 pm AEDT
Discover our authors
Romain Fournier
Chief Editor
Tommy Douziech
Senior Analyst
Kevin Smith
Journalist
Maya Patel
Analyst
Tony Grandsire
Junior Analyst
- Stock Market
- Our authors
- Christophe F. Grosset
